Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...